|
|
|
|
QLT program finds no dose response with latanoprost punctal plug delivery system
VANCOUVER, British Columbia - Patients with open-angle glaucoma or ocular hypertension who received one of three formulations of latanoprost delivered via QLT's punctal plug delivery system failed to achieve a 5 mm Hg or more drop in mean IOP in two phase 2...
|
|
|
NiCox, Bausch & Lomb Ink $179.5M Deal in Glaucoma
Shares in NiCox SA gained almost 11 percent during trading on news that privately held eyecare firm Bausch & Lomb Inc.is stepping in to fill the gap created by the departure of its former partner Pfizer Inc. on the development of the glaucoma and...
|
|
|
NiCox, Bausch&Lomb Ink $179.5M Deal in Glaucoma
Shares in NiCox SA gained almost 11 percent during trading on news that privately held eyecare firm Bausch & Lomb Inc.is stepping in to fill the gap created by the departure of its former partner Pfizer Inc. on the development of the glaucoma and...
|
|
|
Frances NicOx licenses glaucoma drug to Bausch & Lomb
NicOx has signed up a new partner for the investigational glaucoma drug it reacquired the rights for from Pfizer in a deal that could be worth almost $180 million.The US-based eye healthcare giant Bausch & Lomb is stepping in to develop and commercialise...
|
|
|
NiCox, Bausch & Lomb Ink $179.5M Deal in Glaucoma
NiCox SA said privately held eye care firm Bausch & Lomb Inc.is stepping in to fill the gap created by the departure of its former partner Pfizer Inc. on the development of the glaucoma and ocular hypertension drug NCX 116 (previously PF-03187207).
|
|
|
Timolol is well-tolerated for further pressure control in glaucoma
San Francisco?Timolol maleate 0.5%/sorbitol complex (Istalol, ISTA Pharmaceuticals) is a convenient, effective, and well-tolerated choice for adjunctive therapy in patients taking a prostaglandin analogue who need further IOP control, according to the results...
|
|
|
Switching drugs to combat dryness may not stop symptomatic complaints
San Antonio, TXSwitching to another prostaglandin analogue that does not contain benzalkonium chloride (BAK) may not be the answer for managing complaints from patients of dryness and irritation while using latanoprost 0.005% (Xalatan, Pfizer), according...
|
